Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 5,571 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Degenerative Conditions, Neurologic Clear all

Conditions: Health Promotion
Interventions: Usual Care, Psycho-education, Psycho-education plus physical exercise; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Parkinson's Disease, Freezing of Gait
Interventions: ATM FOG in PD; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Alzheimer's Disease, Dementia
Interventions: Placebo, Medication Therapy Management (MTM), Scopolamine patch; Other · Drug
Lead sponsor: Daniela Moga; Other
Eligibility: 65 Years to 101 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Dementia, Alzheimer's Disease
Interventions: Preventing Loss of Independence through Exercise (PLIE), Usual Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atunomic Neuropathy
Interventions: kinesiology tape around the hip, knee and ankle joints, No kinesiology tape around the hip, knee and ankle joints; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions: MAPLE; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month to 100 Years
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2099
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: ITI-214, Placebo; Drug · Other
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Durham, North Carolina

Conditions: Mild Cognitive Impairment
Interventions: Jawbone Up, Physical Activity Education, ActivPAL; Device · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Neurofibromatosis Type 1
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 6 Years to 9 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cardiac Amyloidosis
Interventions: [68Ga]CBP8 PET/MRI; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
Interventions: Seated exercise; Behavioral
Lead sponsor: Burke Medical Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Spine Fusion, Lumbar Spine Degeneration, Pain, Postoperative, Lumbar Spine Spondylosis
Interventions: Zolpidem Tartrate 10 mg, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson's Disease
Interventions: levetiracetam, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 30 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Down Syndrome, Alzheimer's Disease
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 45 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: ALS
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Ann Arbor, Michigan + 10 more

Conditions: Primary Lateral Sclerosis, Adult, 1
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Alzheimer's Disease, Dementia
Interventions: care management; Behavioral
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 65 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Primary Progressive Aphasia, Dementia, Dementia, Frontotemporal, Alzheimer Disease, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration, Apraxia, Motor, Dysarthria, Communication Disorders, Language Disorders, Speech Disorders, Neurocognitive Disorders, Aphasia, Bilingual Aphasia
Interventions: Video-Implemented Script Training for Aphasia (VISTA), Lexical Retrieval Training (LRT); Behavioral
Lead sponsor: Stephanie Grasso; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer Disease, End of Life, Caregiver Burden, Caregiver Burnout, Patient Participation, Self Efficacy
Interventions: Palliative Care Training; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 21 Years and older
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research; Other
Eligibility: 30 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2033
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more

Conditions: HR+/HER2-negative Breast Cancer
Interventions: TOS-358, Fulvestrant, Palbociclib, Ribociclib; Drug
Lead sponsor: Totus Medicines; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more

Conditions: Alzheimer Disease
Interventions: [11C]-CS1P1; Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Caregiver Stress: Interventions to Promote Health and Wellbeing

Atomoxetine for Freezing of Gait in Parkinson's Disease

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia

Proprioception and Sensorimotor Control in Hereditary Sensory and Autonomic Neuropathy

Study of an Intervention to Improve Problem List Accuracy and Use

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

Intervention to Reduce Sedentary Time

Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis

Home Based Tele-exercise for People With Chronic Neurological Impairments

The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia

Genomic Translation for Amyotrophic Lateral Sclerosis Care

"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"

Care Management for Patients With Alzheimer Disease and Their Family Caregivers

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Investigation of Inflammation Using [C-11]-CS1P1